Engineering of new biomaterials and biopharmaceuticals for the diagnosis and treatment of the cerebrovascular and neurodegenerative diseases
Public support
Provider
Ministry of Education, Youth and Sports
Programme
—
Call for proposals
—
Main participants
Fakultní nemocnice u sv. Anny v Brně
Contest type
OP - EU Operational Programme
Contract ID
16_026/0008451-01
Alternative language
Project name in Czech
Inženýrství nových biomateriálů a biofarmak pro diagnózu a léčbu cerebrovaskulárních a neurodegenerativních onemocnění
Annotation in Czech
Cílem projektu je řešit definované problémy projektu, a to díky jedinečné expertíze a dlouhodobým zkušenostem akademických, klinických a průmyslových partnerů zahrnutých v tomto projektu. Žadatel a partneři projektu budou těžit z široké expertízy akademických partnerů v oborech molekulární biologie, buněčné biologie, mikrobiologie, imunologie, proteinové chemie a informatiky, stejně tak klinické neurologie a ze zkušeností s vývojem produktů s vysokou přidanou hodnotou v oborech biotechnologie a biomedicíny průmyslovými partnery.
Scientific branches
R&D category
IF - RDI infrastructure
OECD FORD - main branch
10608 - Biochemistry and molecular biology
OECD FORD - secondary branch
30104 - Pharmacology and pharmacy
OECD FORD - another secondary branch
30103 - Neurosciences (including psychophysiology)
CEP - equivalent branches <br>(according to the <a href="http://www.vyzkum.cz/storage/att/E6EF7938F0E854BAE520AC119FB22E8D/Prevodnik_oboru_Frascati.pdf">converter</a>)
CE - Biochemistry<br>EB - Genetics and molecular biology<br>FH - Neurology, neuro-surgery, nuero-sciences<br>FR - Pharmacology and apothecary chemistry
Completed project evaluation
Provider evaluation
U - Uspěl podle zadání (s publikovanými či patentovanými výsledky atd.)
Project results evaluation
A detailed analysis of the staphylokinase protein was performed. With this knowledge, future modifications of staphylokinase can now be precisely targeted to make thrombolytic therapy up to ten thousand times more effective. The design of entirely new mutants has been completed. The project partners, the company Contipro a.s., have completed patent protection of entirely new hyaluronic acid-based biomaterials and BioVendor - Laboratorní medicína a.s., in collaboration with the Stroke team of FNUSA-ICRC, have developed and validated clinical samples essays for early diagnosis of stroke. Robust production of APOE protein was established and studies on its aggregation, phase separation and interaction with small molecules were initiated. The results are reported in the RIV database. The project has produced 4 patents, over 50 peer-reviewed publications, more than 30 funct. samples, 4 utility models, several soft. developed and 1 prototype.
Solution timeline
Realization period - beginning
Sep 1, 2018
Realization period - end
Jun 30, 2023
Project status
U - Finished project
Latest support payment
Mar 14, 2023
Data delivery to CEP
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data delivery code
CEP24-MZ0-EF-U
Data delivery date
Jun 17, 2024
Finance
Total approved costs
112,031 thou. CZK
Public financial support
31,337 thou. CZK
Other public sources
0 thou. CZK
Non public and foreign sources
0 thou. CZK